Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion.
GLP-1 drugs like liraglutide work through different mechanisms depending on metabolic state, suggesting personalized approaches based on individual metabolic phenotypes.
Using human islets from 112 donors stratified by HbA1c and tanycyte-specific GLP-1R knockout mice, this Diabetologia study demonstrates that liraglutide operates through three complementary, metabolic-state-dependent pathways: brain tanycyte-mediated action predominates in healthy conditions, direct islet effects emerge during glucose intolerance, and insulin-independent mechanisms maintain efficacy in advanced T2D. This mechanistic framework supports precision stratification of patients receiving GLP-1 therapy based on their metabolic phenotype.
What the study was
- Study design
- Mechanistic study: human pancreatic islets + tanycyte-specific GLP-1R knockout mice
- Population
- Human islet donors stratified by HbA1c (normoglycemic, glucose-intolerant, T2D); transgenic mice
- Sample size
- 112
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Diabetologia
Why it surfaced
Novel mechanistic framework explaining liraglutide variable response across metabolic states; human islets n=112; GLP-1 mechanism stratification could inform personalized T2D treatment; Diabetologia top-tier journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.